Sign in

Becky Wei

Vice President and Equity Research Analyst at Citigroup Inc.

Becky Wei is a Vice President and Equity Research Analyst at Citi, specializing in healthcare sector research with a focus on biotechnology and pharmaceutical companies. She covers a portfolio of major healthcare firms such as AbbVie, Eli Lilly, and Vertex Pharmaceuticals, delivering detailed investment analysis and maintaining strong coverage accuracy. Wei began her analyst career at Citi in the early 2020s, following previous positions in healthcare equity research at boutique asset management firms, and has rapidly advanced due to her analytical rigor. She holds FINRA Series 7 and Series 63 licenses and is recognized for her in-depth industry knowledge and meticulous coverage of key pharma companies.

Becky Wei's questions to Cheetah Mobile (CMCM) leadership

Question · Q2 2025

Becky Wei inquired about the sales performance of Cheetah Mobile's domestic cloud robot business, which saw 100% growth in Q2, and the expected incremental revenue contribution from the UFactory robotic arm acquisition starting in H2. She asked for details on revenue growth drivers for both cloud robots and robotic arms, and the sustainability of this high growth.

Answer

Chairman and CEO Fu Sheng highlighted that the triple-digit growth in domestic voice-enabled robots was primarily due to the application of large language models, significantly improving user satisfaction and effectiveness. He noted efforts to expand multi-language capabilities for voice robots overseas. Regarding UFactory, Fu Sheng explained that the acquisition, completed in July, brings a profitable collaborative robotic arm business with significant overseas revenue and high-profit margins, aligning with Cheetah Mobile's strategy to focus on specific, scalable scenarios. He emphasized that while the robotics market is exciting, commercial adoption depends on clear ROI and that the company is exploring combinations of wheeled robots with arms, but commercialization requires more time.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts